This Small Biotech Company Touts Promising Data For Alzheimer’s Candidate
BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…
BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’
Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).
NE3107 is
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Cantor Fitzgerald Initiates Coverage On BioVie with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Charles Duncan initiates coverage on BioVie (NASDAQ:BIVI) with a Overweight rating and announces Price Target of $7.
This Low-Float Stock Jumps Around 148%; Here’s 64 Biggest Movers From Yesterday
Gainers
United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers
Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
BioVie Announces Patent Issuance Covering Ascites Treatment With BIV201
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and
